Alona Muzikansky

37.0k total citations · 7 hit papers
272 papers, 23.5k citations indexed

About

Alona Muzikansky is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alona Muzikansky has authored 272 papers receiving a total of 23.5k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Oncology, 88 papers in Pulmonary and Respiratory Medicine and 49 papers in Molecular Biology. Recurrent topics in Alona Muzikansky's work include Lung Cancer Treatments and Mutations (58 papers), Glioma Diagnosis and Treatment (43 papers) and Neurofibromatosis and Schwannoma Cases (25 papers). Alona Muzikansky is often cited by papers focused on Lung Cancer Treatments and Mutations (58 papers), Glioma Diagnosis and Treatment (43 papers) and Neurofibromatosis and Schwannoma Cases (25 papers). Alona Muzikansky collaborates with scholars based in United States, Germany and Netherlands. Alona Muzikansky's co-authors include Jennifer S. Temel, Thomas J. Lynch, William F. Pirl, Vicki A. Jackson, Emily R. Gallagher, Joseph A. Greer, Juliet Jacobsen, Lecia V. Sequist, J. Andrew Billings and Constance Dahlin and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Alona Muzikansky

267 papers receiving 22.9k citations

Hit Papers

Early Palliative Care for Patients with Metastatic Non–Sm... 2007 2026 2013 2019 2010 2007 2008 2008 2017 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
    2010 4.9k citations Jennifer S. Temel, Alona Muzikansky et al. profile →
  2. Isolation of rare circulating tumour cells in cancer patients by microchip technology
    2007 2.9k citations Lecia V. Sequist, Subba R. Digumarthy et al. profile →
  3. Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
    2008 1.3k citations Lecia V. Sequist, Subba R. Digumarthy et al. profile →
  4. First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
    2008 661 citations Lecia V. Sequist, Pasi A. Jänne et al. Journal of Clinical Oncology profile →
  5. Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial
    2017 590 citations Jennifer S. Temel, Elyse R. Park et al. Journal of Clinical Oncology profile →
  6. Effect of Early Palliative Care on Chemotherapy Use and End-of-Life Care in Patients With Metastatic Non–Small-Cell Lung Cancer
    2011 426 citations Alona Muzikansky, Inga T. Lennes et al. Journal of Clinical Oncology profile →
  7. Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer’s disease
    2020 315 citations Alona Muzikansky et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alona Muzikansky United States 71 10.4k 5.5k 5.4k 4.4k 3.3k 272 23.5k
Martha S. Linet United States 86 5.0k 0.5× 4.3k 0.8× 2.6k 0.5× 3.3k 0.8× 2.5k 0.8× 383 26.0k
Carol DeSantis United States 32 13.0k 1.2× 2.1k 0.4× 5.1k 0.9× 7.8k 1.8× 6.4k 2.0× 55 28.2k
Steven Piantadosi United States 88 11.1k 1.1× 1.8k 0.3× 10.1k 1.9× 5.6k 1.3× 3.2k 1.0× 259 30.5k
Julia Brown United Kingdom 72 12.1k 1.2× 1.9k 0.3× 3.9k 0.7× 3.5k 0.8× 2.4k 0.7× 348 25.0k
Ian F. Tannock Canada 95 16.6k 1.6× 2.9k 0.5× 16.7k 3.1× 9.6k 2.2× 8.1k 2.5× 426 44.1k
James E. Herndon United States 100 13.5k 1.3× 1.2k 0.2× 15.2k 2.8× 8.1k 1.8× 5.8k 1.8× 482 37.5k
Amy Berrington de González United States 61 3.9k 0.4× 1.6k 0.3× 3.1k 0.6× 1.9k 0.4× 1.8k 0.6× 219 19.3k
Ravi Bhatia United States 85 5.9k 0.6× 4.5k 0.8× 2.1k 0.4× 4.8k 1.1× 1.2k 0.4× 463 21.8k
Frédéric Amant Belgium 66 7.2k 0.7× 1.8k 0.3× 3.2k 0.6× 3.7k 0.8× 3.2k 1.0× 554 21.9k
Jill S. Barnholtz‐Sloan United States 69 7.1k 0.7× 1.3k 0.2× 9.3k 1.7× 11.6k 2.7× 7.6k 2.3× 435 41.2k

Countries citing papers authored by Alona Muzikansky

Since Specialization
Citations

This map shows the geographic impact of Alona Muzikansky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alona Muzikansky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alona Muzikansky more than expected).

Fields of papers citing papers by Alona Muzikansky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alona Muzikansky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alona Muzikansky. The network helps show where Alona Muzikansky may publish in the future.

Co-authorship network of co-authors of Alona Muzikansky

This figure shows the co-authorship network connecting the top 25 collaborators of Alona Muzikansky. A scholar is included among the top collaborators of Alona Muzikansky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alona Muzikansky. Alona Muzikansky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dagogo‐Jack, Ibiayi, Alissa J. Cooper, Justin F. Gainor, et al.. (2024). Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study. Lung Cancer. 199. 108003–108003. 1 indexed citations
2.
Mak, Raymond H., Michael Lanuti, Alona Muzikansky, et al.. (2024). The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. The Oncologist. 29(7). 609–618. 8 indexed citations
3.
Coté, Gregory M., Bose Kochupurakkal, T. Khanh, et al.. (2024). A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors. Clinical Cancer Research. 31(1). 35–44. 4 indexed citations
4.
Li, Shuang, Limeng Wu, Yanling Zhang, et al.. (2024). Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer. British Journal of Cancer. 131(10). 1683–1693. 5 indexed citations
5.
Ho, Alice Y., Stephen L. Shiao, Jonathan Chen, et al.. (2024). PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Journal of Clinical Oncology. 42(36). 4282–4293. 6 indexed citations
6.
7.
Jordan, Justin T., Roberta L. Beauchamp, Alona Muzikansky, et al.. (2023). Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2. Neuro-Oncology Advances. 5(1). vdad041–vdad041. 10 indexed citations
8.
Kandil, Dina, et al.. (2023). Translational Potential of Fluorescence Polarization for Breast Cancer Cytopathology. Cancers. 15(5). 1501–1501. 1 indexed citations
9.
Park, Elyse R., Alona Muzikansky, Joanna M. Streck, et al.. (2022). Patients With Serious Mental Illness Can Engage in Tobacco Treatment Trials and Tobacco Cessation Interventions During Cancer Treatment. JCO Oncology Practice. 19(2). e238–e247.
10.
Dagogo‐Jack, Ibiayi, Philicia Moonsamy, Justin F. Gainor, et al.. (2021). A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. Journal of Thoracic Oncology. 16(5). 850–859. 40 indexed citations
11.
Tessier, Shannon N., Uyen Ho, Alona Muzikansky, et al.. (2021). Isolation of intact extracellular vesicles from cryopreserved samples. PLoS ONE. 16(5). e0251290–e0251290. 13 indexed citations
12.
Vries, Reinier J. de, Stephanie E. J. Cronin, Ehab Hafiz, et al.. (2020). Cell release during perfusion reflects cold ischemic injury in rat livers. Scientific Reports. 10(1). 1102–1102. 17 indexed citations
13.
Lorenzano, Svetlana, Natalia S. Rost, Muhib Khan, et al.. (2019). Early molecular oxidative stress biomarkers of ischemic penumbra in acute stroke. Neurology. 93(13). e1288–e1298. 35 indexed citations
14.
Pennell, Nathan A., Joel W. Neal, Jamie E. Chaft, et al.. (2018). SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 37(2). 97–104. 137 indexed citations
15.
Campo, Meghan, David E. Gerber, Justin F. Gainor, et al.. (2016). Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. Journal of Thoracic Oncology. 11(11). 2022–2026. 71 indexed citations
16.
Blakeley, Jaishri O., Xiaobu Ye, Dan G. Duda, et al.. (2016). Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas. Journal of Clinical Oncology. 34(14). 1669–1675. 86 indexed citations
17.
Merker, Vanessa L., Miriam A. Bredella, Wenli Cai, et al.. (2014). Relationship between whole‐body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. American Journal of Medical Genetics Part A. 164(6). 1431–1437. 44 indexed citations
18.
Zhu, Andrew X., Marek Ancukiewicz, Jeffrey G. Supko, et al.. (2013). Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Clinical Cancer Research. 19(6). 1557–1566. 55 indexed citations
19.
Rizvi, Imran, Jonathan P. Celli, Conor L. Evans, et al.. (2010). Synergistic Enhancement of Carboplatin Efficacy with Photodynamic Therapy in a Three-Dimensional Model for Micrometastatic Ovarian Cancer. Cancer Research. 70(22). 9319–9328. 153 indexed citations
20.
Soupir, Chad P., Jo‐Anne Vergilio, Paola Dal Cin, et al.. (2007). Philadelphia Chromosome-Positive Acute Myeloid Leukemia: A Rare Aggressive Leukemia With Clinicopathologic Features Distinct From Chronic Myeloid Leukemia in Myeloid Blast Crisis. American Journal of Clinical Pathology. 127(4). 642–650. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martha S. Linet Breakdown of academic impact, for papers by Carol DeSantis Breakdown of academic impact, for papers by Steven Piantadosi Breakdown of academic impact, for papers by Julia Brown Breakdown of academic impact, for papers by Ian F. Tannock Breakdown of academic impact, for papers by James E. Herndon Breakdown of academic impact, for papers by Amy Berrington de González Breakdown of academic impact, for papers by Ravi Bhatia Breakdown of academic impact, for papers by Frédéric Amant Breakdown of academic impact, for papers by Jill S. Barnholtz‐Sloan
Rankless by CCL
2026